MotionCell Therpeutics

TURNING 15 YEARS OF REAL-WORLD DATA INTO DISEASE-MODIFYING CELL THERAPY.

An allogeneic, off-the-shelf cell therapy for canine osteoarthritis. Disease-modifying, not just pain relief, validated by 15 years of real-world clinical use.

THE COMPANY

MotionCell Therapeutics is developing a disease-modifying stem cell therapy for canine osteoarthritis, a 2 billion euro plus market. Our allogeneic, off-the-shelf MSC therapy targets the disease itself rather than masking pain, built on a 15-year clinical foundation of 2.000+ treatments across 80+ veterinary clinics in Slovenia and Austria.

Reach out

WHY NOW

Recent product launches have validated the veterinary biologics market, with new entrants reaching blockbuster scale of 120 million euro in first-year sales. That adoption proves the demand, but it is concentrated in therapies that manage symptoms. As the category matures, veterinarians and owners are increasingly looking for options that address the underlying disease and deliver durable, long-term outcomes. MotionCell is positioned as the next-generation answer: a clear disease-modifying claim, a strong safety profile, and pharma-compatible infrastructure.

INVESTMENT CASE

01.

CLINICAL VALIDATION

A 15-year foundation, 2.000+ treatments, documented outcomes, established repeat-dosing safety.

02.

CLEAR DIFFERENTIATION

Allogeneic, off-the-shelf MSC therapy with disease-modifying potential, not pain masking.

03.

PROVEN
DEMAND

Market validated by Librela's 120 million euro first year and accelerating adoption.

04.

SCALABLE MANUFACTURING

GMP pathway via CDMO partnership, validated QC and potency assays, built for commercial scale.

05.

LOGISTICS ADVANTAGE

Validated -20°C storage with 2-month shelf life, no LN2 or -80°C complexity.

06.

COMMERCIAL FOOTPRINT

An established clinic network across CEE as the base for rollout.

THE OPPORTUNITY

We are advancing toward EMA registration and commercial launch, building on real-world clinical validation and an established veterinary network. MotionCell is positioned for a strategic partnership or acquisition by a leading veterinary pharma company.